Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
This PKI news page is best understood in the context of the information provided for Revvity, Inc. (NYSE: RVTY), which appears in the supplied news releases. While PKI historically referred to PerkinElmer in analytical laboratory instrument manufacturing, the current news flow in the input is associated with Revvity, a health science company whose activities span discovery to development, and diagnosis to cure.
The news items describe Revvity as providing health science solutions, technologies, expertise, and services, with focus areas that include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. They also note that Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments, and that it is part of the S&P 500 index with customers in more than 160 countries.
Across the sample releases, typical news topics include quarterly financial results, dividend declarations, product launches in diagnostics and life sciences, and participation in healthcare investor conferences. Examples in the input include announcements of new reagent technologies for drug discovery, reference standards for oncology diagnostic testing workflows, and automated analytical platforms for specialty testing, as well as updates on earnings calls and financial performance.
For users researching PKI, this page therefore functions as an entry point into the more recent narrative presented under Revvity’s RVTY symbol in the provided material. Readers can use the news feed to follow themes such as health science product introductions, diagnostics and life sciences workflow tools, and financial reporting, as reflected in the supplied press releases.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PerkinElmer, Inc. (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, scheduled for payment on August 11, 2023. Shareholders on record as of July 21, 2023 will be eligible to receive this payment. In 2022, the company reported revenues of approximately $3.3 billion and serves customers globally across 190 countries. As a component of the S&P 500 index, PerkinElmer remains a significant player in the life sciences and diagnostics sector, focusing on providing comprehensive solutions for disease diagnosis and drug discovery. The company is set to undergo a name change in the second quarter of 2023, reinforcing its commitment to innovation and market leadership.
PerkinElmer Inc. (NYSE: PKI) will release its first quarter 2023 financial results on May 11, 2023, before market open. A conference call hosted by CEO Prahlad Singh and CFO Max Krakowiak is scheduled for 8:00 a.m. ET on the same day. The company, which is undergoing a name change in the second quarter of 2023, reported approximately $3.3 billion in revenue for 2022 and serves customers across 190 countries. As a significant player in the S&P 500 index, PerkinElmer focuses on providing innovative solutions for disease diagnosis and drug discovery.
Parkland Corporation (TSX: PKI) announced a dividend of $0.34 per share, to be paid on April 14, 2023, for shareholders of record by March 22, 2023. The ex-dividend date is set for March 21, 2023. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes, reflecting Parkland's commitment to returning value to its shareholders. The company's extensive operations span 25 countries, with approximately 4,000 retail locations across Canada, the U.S., and the Caribbean, highlighting its significant market presence and strategic growth initiatives.
PerkinElmer Inc. (NYSE: PKI) has completed the divestiture of its Applied, Food, and Enterprise Services businesses to New Mountain Capital. This strategic move allows PerkinElmer to focus on its new Life Sciences and Diagnostics company, which aims to drive scientific innovation and improve global health outcomes. The company plans to unveil a new name and ticker symbol in Q2 2023, pending shareholder approval. With approximately $3.3 billion in revenue in 2022 and operations in 190 countries, the restructured organization is poised for growth and will maintain strong commitments to service and corporate citizenship.
PerkinElmer (NYSE: PKI) announced its participation in the virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum scheduled for March 21, 2023, at 2:15 p.m. ET. Senior executives Steve Willoughby and Alan Fletcher will discuss the company's strategic priorities. Registration for the event is available here. A live audio webcast will be accessible on the company’s website, with a replay available for 30 days following the event.
PerkinElmer, a leader in the life sciences sector, has unveiled the EnVision® Nexus™ system, its most advanced multimode plate reader, at SLAS2023. This innovative platform enhances high-throughput screening (HTS) capabilities, significantly supporting drug discovery by allowing researchers to screen millions of samples with improved speed and accuracy. Additionally, PerkinElmer introduced the Zephyr® G3 NGS iQ™ workstation for automating NGS library preparation, further enhancing laboratory efficiency. With its robust portfolio and commitment to advancing scientific research, PerkinElmer aims to drive R&D productivity across various applications.